Kalinichev Mikhail
Known title: HEAD OF TRANSLATIONAL SCIENCECIK: 0002123907
Associated companies
Transaction History
| ADXN | ▲ Buy | Grant | 306,765 | $0 | 9/2/2026 | View on chart |
| ADXN | ▼ Sell | Other | 306,765 | $0 | 9/2/2026 | View on chart |
| ADXN | ▲ Buy | Grant | 306,765 | $0 | 9/2/2026 | View on chart |
| ADXN | ▼ Sell | Other | 306,765 | $0 | 9/2/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Addex Therapeutics Reports Q2 2026 Results and Management Changes
Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.
Addex Therapeutics Reports Q2 2026 Results and Management Changes. Addex Therapeutics announced executive management changes alongside its Q2 2026 earnings report. The company reported sales of $12,650, a decrease from $44,031 in the same period last year. Additionally, the company provided an update on its corporate status during the half-year results release.